Investors | Co-Diagnostics, Inc. - Financial Information

Financial Information

This section of the Co-Diagnostics InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing.

Please note: All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes. Co-Diagnosticsassumes no responsibility for the accuracy of this data and provides it for informational purposes only.

NASDAQCODX

Beta	(1.70)
Shares Outstanding	28.3M
Average Volume (10 days)	3.4M
Qtrly Dividend (Ann. Yield)	-- (--)

Per Share Data

Earnings (TTM)	$0.90
Sales (TTM)	$1.68
Book Value (MRQ)	$1.87
Cash Flow (TTM)	$0.27
Cash (MRQ)	$27,280,362.00

Analyst Views

Current Mean Recommendation	Strong Buy

Strong Buy	2
Buy	0
Hold	0
Underperform	0
Sell	0

Recent Insider Transactions

Reed L. Benson CFO and Secretary	(10,476) Dispose Nov 25, 2020
Reed L. Benson CFO and Secretary	(89,524) Sell Nov 25, 2020
Dwight H Egan Director, Chief Executive Officer	(5,236) Dispose Nov 24, 2020
Dwight H Egan Director, Chief Executive Officer	(44,764) Sell Nov 24, 2020
Dwight H Egan Director, Chief Executive Officer	(8,431) Dispose Nov 23, 2020

Recent SEC Filings

4 Insider Buy/Sell	Nov 30, 2020
4 Insider Buy/Sell	Nov 25, 2020
4 Insider Buy/Sell	Nov 24, 2020
4 Insider Buy/Sell	Nov 24, 2020
4 Insider Buy/Sell	Nov 24, 2020

Currency in USD.
Quote data delayed by at least 15 minutes.
Earnings and Analyst data provided by Zacks.
Insiders data provided by Morningstar.

Co-Diagnostics is a molecular diagnostics company with a unique mathematical approach to DNA test design. Our products offer a unique value proposition, making the detection of infectious disease and genetic disorders far more affordable worldwide.

Click here to learn more

Co-Diagnostics, Inc.
2401 South Foothill Dr, Suite D
Salt Lake City, Utah 84109
United States

1 (801) 438-1036

info@codiagnostics.com

COMPANY

Site Terms and Conditions

Privacy Policy

Co-Diagnostics, Inc. Issues Operational Update

Salt Lake City, Utah – September 1, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, issued the following statement concerning the progress of the...